Discussion 'Cancer'
Understanding the approach to integrative oncology
Research suggests that cancer patients are interested in using additional interventions that may help improve the efficacy of conventional cancer treatments, increase their chance of survival, and/or reduce their symptom burden associated with cancer or treatments. They are also looking…
Waldenstrom’s Macroglobulinemia: Advances in Treatments
Waldenstrom’s macroglobulinemia (WM) is a lymphoma, or cancer of the lymphatic system. The disease begins in a type of white blood cell called a B-lymphocyte, which normally matures into a plasma cell. In WM, there is a malignant change to…
Off-the-shelf Immune Drug for Aggressive Multiple Myeloma: Teclistamab
U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for teclistamab in the treatment of relapsed or refractory multiple myeloma. This follows a PRIME (PRIority MEdicines) designation from the European Medicines Agency (EMA) received earlier this year. …
Lung Cancer Mutations and Treatment Advances
Lung cancer, the most common cancer type with the highest mortality, can largely be categorized by the genetic mutations that cause it. By targeting the specific genetic mutation behind a patient’s cancer, targeted therapies have enabled increasing numbers of patients…
Goals and challenges of developing a patient focused myeloma center of excellence
The multiple myeloma treatment field has undergone several changes over the past 10-20 years. The average overall survival has changed from 1-3 years to 10-20 years. Yet, there is no established curative therapy for multiple myeloma. However, advanced monitoring with…